Dashboard
1
High Management Efficiency with a high ROE of 19.18%
2
Company's ability to service its debt is strong with a healthy EBIT to Interest (avg) ratio of 15.75
3
Poor long term growth as Operating profit has grown by an annual rate 12.46% of over the last 5 years
4
Flat results in Jun 25
5
With ROE of 18.37%, it has a very expensive valuation with a 5.22 Price to Book Value
6
Company is among the highest 1% of companies rated by MarketsMojo across all 4,000 stocks
7
Below par performance in long term as well as near term
Stock DNA
Pharmaceuticals & Biotechnology
SEK 3,826 Million (Small Cap)
28.00
NA
0.01%
-0.15
17.78%
4.49
Revenue and Profits:
Net Sales:
191 Million
(Quarterly Results - Jun 2025)
Net Profit:
38 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-6.98%
0%
-6.98%
6 Months
-15.12%
0%
-15.12%
1 Year
-26.54%
0%
-26.54%
2 Years
-10.88%
0%
-10.88%
3 Years
-31.5%
0%
-31.5%
4 Years
-51.15%
0%
-51.15%
5 Years
-48.56%
0%
-48.56%
CellaVision AB for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
8.83%
EBIT Growth (5y)
12.46%
EBIT to Interest (avg)
15.75
Debt to EBITDA (avg)
Net Debt is too low
Net Debt to Equity (avg)
-0.19
Sales to Capital Employed (avg)
0.87
Tax Ratio
20.41%
Dividend Payout Ratio
42.37%
Pledged Shares
0
Institutional Holding
0.00%
ROCE (avg)
26.30%
ROE (avg)
19.18%
Valuation key factors
Factor
Value
P/E Ratio
28
Industry P/E
Price to Book Value
5.22
EV to EBIT
21.16
EV to EBITDA
17.85
EV to Capital Employed
5.98
EV to Sales
5.55
PEG Ratio
6.74
Dividend Yield
0.01%
ROCE (Latest)
28.26%
ROE (Latest)
18.37%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bearish
Bearish
RSI
No Signal
No Signal
Bollinger Bands
Bearish
Bearish
Moving Averages
Bearish (Daily)
KST
Bearish
Bearish
Dow Theory
Mildly Bullish
No Trend
OBV
Mildly Bullish
No Trend
Shareholding Snapshot : Dec 2016
Shareholding Compare (%holding) 
Majority shareholders
Foreign Institutions
Domestic Funds
Held in 0 Schemes (0%)
Foreign Institutions
Held by 1 Foreign Institutions (0.0%)
Strategic Entities with highest holding
Highest Public shareholder
Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY
Jun'25
Jun'24
Change(%)
Net Sales
191.30
187.80
1.86%
Operating Profit (PBDIT) excl Other Income
59.60
59.70
-0.17%
Interest
4.10
2.60
57.69%
Exceptional Items
0.00
0.00
Consolidate Net Profit
37.60
38.50
-2.34%
Operating Profit Margin (Excl OI)
263.00%
261.50%
0.15%
USD in Million.
Net Sales
YoY Growth in quarter ended Jun 2025 is 1.86% vs 10.67% in Jun 2024
Consolidated Net Profit
YoY Growth in quarter ended Jun 2025 is -2.34% vs 10.95% in Jun 2024
Annual Results Snapshot (Consolidated) - Dec'24
Dec'24
Dec'23
Change(%)
Net Sales
723.20
677.30
6.78%
Operating Profit (PBDIT) excl Other Income
218.70
206.80
5.75%
Interest
1.90
3.30
-42.42%
Exceptional Items
0.00
0.00
Consolidate Net Profit
140.70
130.30
7.98%
Operating Profit Margin (Excl OI)
245.70%
246.60%
-0.09%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2024 is 6.78% vs 5.94% in Dec 2023
Consolidated Net Profit
YoY Growth in year ended Dec 2024 is 7.98% vs 10.14% in Dec 2023
About CellaVision AB 
CellaVision AB
Pharmaceuticals & Biotechnology
CellaVision AB is a Sweden-based company active in the medical technology sector. The Company develops and sells digital solutions for medical microscopy, as well as products enabling blood cell analysis and morphology diagnosis. CellaVision AB’s product portfolio consists of analyzers for automated medical microscopy analysis and software applications designed for remote access, competency testing and education. The analyzers include such brands as CellaVision DM96 and CellaVision DM1200, whereas the software applications are divided into CellaVision Body Fluid Application, CellaVision Remote Review Software and CellaVision Competency Software, among others. The Company operates four subsidiaries, based in Sweden, Canada, the United States and Japan. In June 2014, CellaVision AB acquired technology platform from Clear Lake Medical Foundation.
Company Coordinates 
Company Details
Mobilvagen 12 , LUND None : 223 62
Registrar Details






